Jiang Muzhong and Vas Narasimhan also greeted the employees around the world by mail. Vas Narasimhan first thanked the current CEO Jiang Muzhong and Chairman Jrg Reinhardt for their guidance and trust in the mail, and expressed their honour to lead Novartis to the next stage of growth. And global influence. Just a few days ago, the FDA approved Novartis's CAR-T therapy Kymriah (tisagenlecleucel), the first approved CAR-T therapy in human history, which gave Jiang Muzhong a perfect ending during his tenure. . Before entering the Novartis, Jiang Muzhong was the CEO of Heinz Europe. After entering Novartis, he promoted Novartis's research and development of oncology drugs, and increased investment in emerging markets such as China, expanding employees and achieving better returns. Jiang Muzhong's former appointment was Wei Sile, which promoted the listing of Novartis's classic drug Gleevec, and made great contributions to Sino-Swiss technology exchanges. Regarding the incoming Vas Narasimhan, according to relevant information, he graduated from the University of Chicago with a degree in Biological Science. He then entered the Harvard Medical School and the Harvard Kennedy School of Politics. He received his Ph.D. in Medicine and Master of Public Policy, respectively. He entered the first company in 2002. McKinsey joined Novartis in 2005 and is currently the head of the global pharmaceutical development and chief medical officer at Novartis. He previously served as global director of the Sandoz Pharmaceuticals and Oncology Business Unit, responsible for the department's biosimilar pipeline, before Sandoz. He has served as the global director of Novartis Vaccine R&D, and the head of Novartis Vaccine North America, President of Novartis Vaccine and Diagnostics USA. Vas Narasimhan led the team to achieve good results in drug development, including: anti-inflammatory drug kanamycin (canakinumab) for the treatment of heart disease, a new generation of migraine drugs developed in collaboration with Amgen, and treatment of relapsing multiple sclerosis BAF312 (siponimod), a range of biosimilars, and additional data for drugs such as the psoriasis drug Consenttyx. For this important task, Vas Narasimhan promised in the company statement that we will continue to carry forward our tradition of bringing leading innovative products to patients around the world. The launch of our latest products, strong R&D pipelines, extensive innovation capabilities, world-class leadership teams and dedicated colleagues have given me confidence in our future. The company will continue its global efforts to obtain critical data on transformative therapies that can have a significant impact on patients while earning billions of dollars in revenue for the company.
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bodybuildingoil.com